ProMIS Neurosciences (NASDAQ:PMN) Stock Price Down 4.9%

ProMIS Neurosciences, Inc. (NASDAQ:PMNGet Free Report)’s share price traded down 4.9% during trading on Thursday . The company traded as low as $1.96 and last traded at $1.96. 17,865 shares changed hands during trading, a decline of 88% from the average session volume of 150,946 shares. The stock had previously closed at $2.06.

Analyst Upgrades and Downgrades

Separately, Leede Jones Gab reissued a “speculative buy” rating on shares of ProMIS Neurosciences in a research report on Monday, July 17th.

Check Out Our Latest Stock Analysis on PMN

ProMIS Neurosciences Stock Down 4.9 %

The company has a market capitalization of $16.81 million, a PE ratio of -0.75 and a beta of 0.67. The company has a 50-day moving average price of $3.06 and a two-hundred day moving average price of $4.44.

About ProMIS Neurosciences

(Get Free Report)

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.

Featured Stories

Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with's FREE daily email newsletter.